Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride

Journal of Clinical Pharmacology

Volumn 36, Issue 12, 1996, Pages 1169-1178

  Samara, Emil E ^a   Hosmane, Bala ^a   Locke, Charles ^a   Eason, Carolyn ^a   Cavanaugh, John ^a   Granneman, G Richard ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROSTANOLONE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TESTOSTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PROSTATE HYPERTROPHY; STEADY STATE; TESTOSTERONE BLOOD LEVEL;

EID: 0030466214     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04172.x     Document Type: Article

References (11)

1. Achari R, Laddu A: Terazosin: a new alpha adrenoceptor blocking drug. J Clin Pharmacol 1992;32:520-523.
2. Peters DH, Sorkin EM: Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993; 46(1):177-208.
3. Sudduth SL, Koronkowski MJ: Finasteride: the first 5α-reductase inhibitor. Pharmacotherapy 1993;13:309-329.
4. Lepor H: A department of veteran affairs cooperative randomized placebo controlled trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical BPH (abstract). J Urol 1996; 155S:587A.
5. Constazer ML, Matuszowski BK, Bayne WF: High-performance liquid chromatographic method for the determination of finasteride in human plasma at therapeutic doses. J Chromatogr 1991; 566:127-134.
6. Gibaldi M, Perrier D: Pharmacokinetics. Second Edition. New York: Marcel Dekker, 1982;1-111, 319-353, 409-417.
7. Hollander M, Wolfe D. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1973.
8. SAS Institute: SAS/STAT User's Guide. Volume 2, Version 6, Fourth Edition. Cary, NC:SAS Institute, 1990.
9. Hill SJ, Lawrence SL, Lepor H: New use for alpha blockers: benign prostatic hyperplasia. Am Fam Physician 1994;49:1885-1888.
10. Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SL: Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Disps 1995;23:1126-1135.
11. Winchell GA, Gregoire S, Taylor AM, Hegland J, Hunninghake DB: Finasteride, a steroid 5α-reductase inhibitor, does not affect the oxidative metabolism of antipyrine. J Clin Pharmacol 1993;33:967-970.